We rank companies based on fund manager, research analyst and news sentiment
AVDL

Avadel Pharmaceuticals
AVDL

$17.33
0.29%
 

About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

Employees: 154

0
Funds holding %
of 6,474 funds
0
Analysts bullish %
of 9 analysts
News positive %

Fund manager confidence

Based on 2023 Q4 SEC filings by fund managers ($100M+ AUM)

166% more call options, than puts

Call options by funds: $11.9M | Put options by funds: $4.45M

150% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 8

42% more capital invested

Capital invested by funds: $559M [Q3] → $792M (+$233M) [Q4]

26% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 27

12% more funds holding

Funds holding: 98 [Q3] → 110 (+12) [Q4]

1.62% more ownership

Funds ownership: 60.85% [Q3] → 62.47% (+1.62%) [Q4]

0% more funds holding in top 10

Funds holding in top 10: 6 [Q3] → 6 (+0) [Q4]

Research analyst outlook

9 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$19
10%
upside
Avg. target
$23
30%
upside
High target
$29
67%
upside

9 analyst ratings

positive
100%
neutral
0%
negative
0%
Needham
Ami Fadia
27%upside
$22
Buy
Reiterated
9 Apr 2024
Craig-Hallum
Chase Knickerbocker
27%upside
$22
Buy
Maintained
5 Mar 2024
Oppenheimer
Francois Brisebois
67%upside
$29
Outperform
Maintained
5 Mar 2024
HC Wainwright & Co.
Oren Livnat
44%upside
$25
Buy
Maintained
5 Mar 2024
Piper Sandler
David Amsellem
33%upside
$23
Overweight
Maintained
5 Mar 2024

Financial journalist opinion